About Hampsbio
Hampsbio is a publicly listed company. Pharmaceutical formulations and freeze-dried food ingredients are manufactured. The company has 34 employees. Its Indian entity Hamps Bio Limited reported revenue of ₹8.80 Cr. Hampsbio offers products and services including Pharmaceutical Formulations and Freeze-Dried Ingredients. Its focus areas include Traditional Pharmaceuticals.
Company details
Operations in the pharmaceutical and food sectors are conducted by Hampsbio, where tablets, capsules, syrups, and injectables are produced alongside freeze-dried fruits, vegetables, herbs, and other ingredients. These products are supplied to business-to-business and business-to-consumer markets, both domestically and internationally. Branded items for direct consumer purchase are also offered, supporting diverse applications in health and nutrition.
- Employees 34
- Stage Public
- SectorsHealthcare
- Website hampsbio.com
- Social YouTube
- Legal Name Hamps Bio Ltd.
- Market Cap₹22.22 Cr
HAMPS · BSE
- Share Price₹25.50
0.00% today
- Revenue₹8.47 Cr
FY 2025-26 · +27.0% YoY
- EBITDA₹0.04 Cr
Margin 0.5%
- Net Profit−₹0.73 Cr
FY 2025-26 · -343.3% YoY
- Debt / Equity0.58
Interest cover -32.0x
- Employee Count34
Associated legal entities of Hampsbio
Hampsbio is associated with 2 registered companies on The Company Check; the primary company is Hamps Bio Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hamps Bio Limited Listed CIN L24233GJ2007PLC049692 | Active | 02 Jan 2007 | Choryasi, Gujarat | ₹8.8 Cr | 34 | 7 | View details |
| Hamps Bio Limited CIN U24233GJ2007PLC049692 | 02 Jan 2007 | Vadodara, Gujarat, India | View details |
Products & Services of Hampsbio
Hampsbio offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and Freeze-Dried Ingredients.
Various medicines and formulations are manufactured and distributed for therapeutic purposes, covering areas like anti-hypertensive and antibiotics
Freeze-dried fruits, vegetables, and herbs are supplied for use in industries such as tea, soup, and nutrition bars, serving B2B and B2C markets
Apps and channels of Hampsbio
its YouTube channel FzyEzy has 120 subscribers and 30 videos.
Videos from Hampsbio
The most watched videos on Hampsbio's YouTube channel, FzyEzy (120 subscribers). Click a video to play it here.
More on FzyEzy.
Board of directors of Hamps Bio Limited (Hampsbio)
Hamps Bio Limited is the primary company behind Hampsbio. The board of Hamps Bio Limited currently have 5 directors; the longest-serving is Shrenikkumar Mountkumar Shah, appointed in 2007. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shrenikkumar Mountkumar Shah DIN 00973690 | Whole-time director | 02 Jan 2007 | 19 yrs 9 mo | Hamps Bio Limited |
| Herrik Mountbaton Shah DIN 01052316 | Managing Director | 02 Jan 2007 | 19 yrs 9 mo | Hamps Bio Limited |
| Jinay Dipakkumar Palrecha DIN 10379873 | Director | 04 Nov 2023 | 2 yrs 11 mo | Hamps Bio Limited |
| Pallavi Herrik Shah DIN 10418931 | Director | 15 Jun 2024 | 2 yrs 4 mo | Hamps Bio Limited |
| Shivali Rajpurohit DIN 11203115 | Director | 25 Aug 2025 | 1 yr 2 mo | Hamps Bio Limited |
IPO & Listings of Hampsbio
Hampsbio is a publicly listed company on the BSE with ticker symbol HAMPS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Dec 2024
- Listed onBSE: 544312
- Listed entityHamps Bio Ltd.
- Exchange sectorHealth technology
- ISININE0QBD01018
- Share price₹24.50 (-3.92% on the day) · 2026-10-14
- Market capitalisation₹22.2 Cr
- EPS (diluted, trailing year)₹-0.85
- Volume (last session)8,000
Financials of Hampsbio
Exchange-reported figures of Hamps Bio Limited, the listed company behind Hampsbio (BSE: HAMPS).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 8.47 | 6.67 |
| Revenue growth | +27.0% | - |
| EBITDA | 0.04 | 0.77 |
| EBITDA margin | +0.5% | +11.5% |
| Profit before tax | (0.70) | 0.40 |
| Net profit | (0.73) | 0.30 |
| Net profit margin | -8.6% | +4.5% |
| EPS (₹) | (0.85) | 0.68 |
| Balance sheet | ||
| Total assets | 15.09 | 11.86 |
| Net worth | 8.10 | 8.80 |
| Total debt | 6.89 | 2.97 |
| Cash & bank | 0.17 | 0.10 |
| Net working capital | 4.47 | 3.38 |
| Cash flow | ||
| Cash from operations | (0.71) | (1.76) |
| Cash from investing | (2.93) | (6.21) |
| Cash from financing | 3.72 | 8.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 8.52 | 6.67 | 6.48 | 5.58 | 5.34 |
| Revenue growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| EBITDA | 0.12 | 0.76 | 1.19 | 0.86 | 0.61 |
| EBITDA margin | +1.4% | +11.4% | +18.4% | +15.4% | +11.4% |
| Profit before tax | (0.61) | 0.39 | 0.67 | 0.35 | 0.09 |
| Net profit | (0.65) | 0.29 | 0.52 | 0.35 | 0.11 |
| Net profit margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Balance sheet | |||||
| Total assets | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Net worth | 8.18 | 8.80 | 3.34 | 1.36 | 1.01 |
| Total debt | 6.40 | 2.97 | 1.05 | 1.74 | 2.04 |
| Cash & bank | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Net working capital | 4.09 | 3.38 | 1.78 | 0.42 | 0.79 |
| Cash flow | |||||
| Cash from operations | (0.37) | (1.76) | (0.29) | 1.23 | 0.33 |
| Cash from investing | (2.93) | (6.21) | (0.37) | (0.75) | 0.51 |
| Cash from financing | 3.23 | 8.00 | 0.67 | (0.48) | (0.94) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 8.47 | 6.67 |
| Revenue growth | +27.0% | - |
| Other income | 0.33 | 0.15 |
| Total expenses | 8.43 | 5.90 |
| Employee cost | 2.45 | 1.81 |
| EBITDA | 0.04 | 0.77 |
| EBITDA margin | +0.5% | +11.5% |
| Depreciation | 0.82 | 0.38 |
| Interest | 0.25 | 0.14 |
| Profit before tax | (0.70) | 0.40 |
| Tax | 0.03 | 0.10 |
| Net profit | (0.73) | 0.30 |
| Net profit margin | -8.6% | +4.5% |
| EPS (₹) | (0.85) | 0.68 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 8.71 | 4.36 |
| Reserves & surplus | (0.61) | 4.44 |
| Shareholders' funds (net worth) | 8.10 | 8.80 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 2.97 | 2.55 |
| Unsecured loans | 3.92 | 0.42 |
| Total debt | 6.89 | 2.97 |
| Total liabilities | 15.09 | 11.86 |
| Assets | ||
| Gross block | 13.81 | 7.18 |
| Net block | 9.10 | 2.49 |
| Capital work in progress | 1.08 | 3.38 |
| Investments | 0.07 | 0.00 |
| Inventories | 2.58 | 2.38 |
| Sundry debtors | 1.59 | 1.19 |
| Cash & bank balances | 0.17 | 0.10 |
| Loans & advances | 0.96 | 0.64 |
| Total current assets | 5.30 | 4.31 |
| Total current liabilities | 0.83 | 0.93 |
| Net working capital | 4.47 | 3.38 |
| Total assets | 15.09 | 11.86 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 0.10 | 0.06 |
| Net cash from operating activities | (0.71) | (1.76) |
| Net cash from investing activities | (2.93) | (6.21) |
| Net cash from financing activities | 3.72 | 8.00 |
| Net change in cash | 0.07 | 0.04 |
| Closing cash | 0.17 | 0.10 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +27.0% | - |
| EBITDA growth | -94.8% | - |
| PBT growth | - | +9997.0% |
| Net income growth | -343.3% | - |
| Profitability & leverage | ||
| Net income margin | -8.6% | +4.5% |
| Return on capital employed | 0.0% | +4.6% |
| Return on net worth | 0.0% | +3.4% |
| Debt / equity | 0.58 | 0.34 |
| Long-term debt / equity | 0.36 | 0.23 |
| Interest cover | -32.05 | 35.90 |
| Efficiency & per share | ||
| Fixed asset turnover | 0.81 | 0.93 |
| Inventory turnover | 3.42 | 2.80 |
| Debtors turnover | 6.09 | 5.61 |
| EPS (₹) | (0.85) | 0.68 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 9.30 | 20.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 8.52 | 6.67 | 6.48 | 5.58 | 5.34 |
| Revenue growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| Other income | 0.33 | 0.15 | 0.03 | 0.01 | 0.00 |
| Total expenses | 8.40 | 5.91 | 5.29 | 4.72 | 4.73 |
| Employee cost | 2.14 | 1.81 | 1.64 | 1.79 | 1.69 |
| EBITDA | 0.12 | 0.76 | 1.19 | 0.86 | 0.61 |
| EBITDA margin | +1.4% | +11.4% | +18.4% | +15.4% | +11.4% |
| Depreciation | 0.81 | 0.38 | 0.40 | 0.34 | 0.33 |
| Interest | 0.25 | 0.14 | 0.15 | 0.18 | 0.19 |
| Profit before tax | (0.61) | 0.39 | 0.67 | 0.35 | 0.09 |
| Tax | 0.04 | 0.10 | 0.15 | 0.00 | (0.02) |
| Net profit | (0.65) | 0.29 | 0.52 | 0.35 | 0.11 |
| Net profit margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 8.71 | 4.36 | 1.96 | 1.50 | 1.50 |
| Reserves & surplus | (0.53) | 4.44 | 1.38 | (0.14) | (0.49) |
| Shareholders' funds (net worth) | 8.18 | 8.80 | 3.34 | 1.36 | 1.01 |
| Secured loans | 2.75 | 2.55 | 0.89 | 1.30 | 1.65 |
| Unsecured loans | 3.65 | 0.42 | 0.16 | 0.44 | 0.39 |
| Total debt | 6.40 | 2.97 | 1.05 | 1.74 | 2.04 |
| Total liabilities | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Assets | |||||
| Gross block | 10.57 | 5.05 | 4.71 | 4.35 | 3.72 |
| Net block | 7.19 | 2.48 | 2.53 | 2.60 | 2.16 |
| Capital work in progress | 1.08 | 3.38 | 0.00 | 0.00 | 0.00 |
| Investments | 2.04 | 0.00 | 0.00 | 0.00 | 0.04 |
| Inventories | 2.44 | 2.38 | 1.23 | 0.37 | 0.57 |
| Sundry debtors | 1.21 | 1.19 | 0.99 | 0.76 | 0.69 |
| Cash & bank balances | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Loans & advances | 0.94 | 0.64 | 0.16 | 0.05 | 0.03 |
| Total current assets | 4.62 | 4.31 | 2.44 | 1.23 | 1.34 |
| Total current liabilities | 0.53 | 0.93 | 0.66 | 0.81 | 0.55 |
| Net working capital | 4.09 | 3.38 | 1.78 | 0.42 | 0.79 |
| Total assets | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 0.10 | 0.06 | 0.05 | 0.05 | 0.15 |
| Net cash from operating activities | (0.37) | (1.76) | (0.29) | 1.23 | 0.33 |
| Net cash from investing activities | (2.93) | (6.21) | (0.37) | (0.75) | 0.51 |
| Net cash from financing activities | 3.23 | 8.00 | 0.67 | (0.48) | (0.94) |
| Net change in cash | (0.06) | 0.04 | 0.01 | 0.00 | (0.10) |
| Closing cash | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| EBITDA growth | -84.2% | -36.1% | +38.4% | +41.0% | - |
| PBT growth | - | -41.8% | +91.4% | +288.9% | +9997.0% |
| Net income growth | -324.1% | -44.2% | +48.6% | +218.2% | - |
| Revenue CAGR (3Y) | +15.2% | +7.7% | - | - | - |
| EBITDA CAGR (3Y) | -48.1% | +7.6% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| Return on capital employed | 0.0% | +6.7% | +20.7% | +15.7% | +8.1% |
| Return on net worth | 0.0% | +4.9% | +20.7% | +24.0% | +8.0% |
| Debt / equity | 0.55 | 0.33 | 0.59 | 1.59 | 2.02 |
| Long-term debt / equity | 0.34 | 0.19 | 0.16 | 0.53 | 0.78 |
| Interest cover | -36.23 | 36.84 | 18.99 | 34.62 | 67.86 |
| Efficiency & per share | |||||
| Fixed asset turnover | 1.09 | 1.37 | 1.43 | 1.38 | 1.44 |
| Inventory turnover | 3.54 | 3.70 | 8.10 | 11.87 | 9.37 |
| Debtors turnover | 7.10 | 6.12 | 7.41 | 7.70 | 7.74 |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 9.39 | 20.20 | 17.06 | 9.09 | 6.70 |
Web traffic of Hampsbio
The website of Hampsbio (hampsbio.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 209.1% vs previous month
Websites whose visitors overlap most with Hampsbio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rits.co | 100% | View details | |||
sunshinechemicals.in | sunshinechemicals.in | 99% | – | ||
saintroylifesciences.com | saintroylifesciences.com | 99% | #15,257,899 | – | |
neutralpharma.com | neutralpharma.com | 98% | #6,928,613 | – | |
thepilltraders.com | thepilltraders.com | 97% | #14,129,667 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Hampsbio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hampsbio
Complete news archive for Hampsbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hampsbio
Hampsbio has 34 employees.
The primary company behind Hampsbio, Hamps Bio Limited, reported revenue of ₹8.80 Cr for FY 2026, up 27% year on year.
Operations in the pharmaceutical and food sectors are conducted by Hampsbio, where tablets, capsules, syrups, and injectables are produced alongside freeze-dried fruits, vegetables, herbs, and other ingredients. These products are supplied to business-to-business and business-to-consumer markets, both domestically and internationally. Branded items for direct consumer purchase are also offered, supporting diverse applications in health and nutrition.
Hampsbio offers Pharmaceutical Formulations and Freeze-Dried Ingredients.
Yes, Hampsbio is publicly traded on BSE under the ticker symbol HAMPS.
Hampsbio operates through Hamps Bio Limited.
The legal entities of Hampsbio currently have 7 directors, including Shrenikkumar Mountkumar Shah, Herrik Mountbaton Shah, Shivali Rajpurohit and others.